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Bacterial resistance to vancomycin: five genes and one 
missing hydrogen bond tell the story 
A plasmid-borne transposon encodes enzymes and regulator proteins that confer 
resistance of enterococcal bacteria to the antibiotic vancomycin. Purification and 
characterization of individual proteins encoded by this operon has helped to 
elucidate the molecular basis of vancomycin resistance. This new understanding 
provides opportunities for intervention to reverse resistance. 
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In the general context of the emergence and re-emergence 
of bacterial resistance to antibiotics, the development 
of clinically consequential resistance by Gram-positive, 
opportunistic pathogens such as enterococci to the gly- 
copeptide antibiotic vancomycin (Fig. 1) is an especially 
compelling cautionary tale of molecular logic that has 
recently been decoded. Given that vancomycin is often the 
therapeutic agent of choice in the treatment of methicillin- 
resistant Staphylococcus aureus infections [1,2] and that van- 
comycin resistance in enterococci had risen dramatically 
from 0.4 % incidence in hospital intensive care units in 
1989 to 13 % by 1993 [3], the specter of transfer of van- 
comycin resistance to p-lactam-insensitive staphylococci 
and streptococci has ominous portent. 
Mode of action of vancomycin 
To deconvolute the molecular logic of the recently 
detected vancomycin resistance, including underlying 
chemical alterations in bacterial cell wall structure and the 
regulation thereof, one must first understand the mecha- 
nism of action of the antibiotic. Vancomycin acts just 
upstream of the penicillin-sensitive, bifunctional transgly- 
cosylases/transpeptidases [4] that add disaccharyl pen- 
tapeptide units to the growing peptidoglycan (PG) cell 
wall and then crosslink peptides within and between 
strands of the PG layer at the external face of the cytoplas- 
mic membrane (Fig. 2a) .The target of vancomycin is actu- 
ally the substrate molecule for the p-lactam-sensitive 
transglycosylase/transpeptidase, namely lipid-PP-disaccha- 
ride-pentapeptide (Fig. 2b). The cup-shaped vancomycin 
molecule binds with high affinity via its concave pocket to 
the N-acyl-D-Ala-D-Ala termini of the as yet uncross- 
linked pentapeptide by way of five hydrogen bonds 
between substrate and antibiotic [5]. 
Binding of vancomycin to the lipid-PP-GlcNAc-penta- 
peptide chains is thought to physically occlude the 
approach and prevent subsequent action of the trans- 
glycosylase/transpeptidase (Fig. 2~). Failure to attach the 
disaccharyl pentapeptide and to execute a crosslink 
lowers the interstrand covalent connectivity, lowers the 
mechanical strength of the PG layer, and renders the 
bacteria susceptible to lysis as osmotic pressure changes 
occur. Vancomycin is effective against Gram-positive 
bacteria such as enterococci, streptococci, and staphylo- 
cocci, but not Gram-negatives such as E. coli or Salmonella 
typhimurium, because the latter have an intact outer mem- 
brane, which serves as a permeability barrier that blocks 
access of the antibiotic to the PG-D-Ala-D-Ala termini in 
the periplasm (Fig. 3). 
Five van genes are necessary and sufficient for resistance 
A series of ground-breaking studies by the infectious- 
disease group at the Pasteur Insititut headed by Patrice 
Courvalin [6] allowed the molecular logic of enterococcal 
resistance to vancomycin to be decoded. They isolated a 
plasmid from bacterial cells in the blood of a cancer 
patient who had died of a fulminant infection by entero- 
cocci that proved resistant to both p-lactam and glycopep- 
tide antibiotics. Courvalin and colleagues determined that 
the plasmid contained the van genes within a transposon. 
They sequenced seven open reading frames (vanS,R,H, 
A,X,Y,Z) and proved by insertion mutagenesis that five 
genes, vanS,R,H,A,X (Fig. 4), were both necessary and 
sufficient to induce a high level (minimal inhibitory con- 
centration of 1000 l.Lg ml-’ vs 1 pg ml-’ for a sensitive 
strain) of antibiotic resistance. From the DNA sequence of 
these genes, they inferred putative functions for four of the 
Fig. 1. Structure of vancomycin produced by Amycolatopsis orientalis. 
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Fig. 2. Steps in the cell wall biosynthetic pathway that are inhibited by vancomycin. (a) The lactam-sensitive transglycosylationitranspep- 
tidation steps of cell wall assembly are accomplished by glycosyl transfer via attack of the ClcNAc 4-hydroxyl group on the Iipid-PP-di- 
saccharide-pentapeptide intermediate to produce elongated strands of glycopeptide. These strands are further crosslinked through 
transpeptidase action which proceeds by attack of the Lys e-NH, (or diaminopimelic acid in Gram-negative hosts) on the D-Ala-D-Ala 
termini of neighboring glycan strands to yield the mature, rigid bacterial cell wall. (b) Vancomycin (black) binds with high affinity to the 
D-Ala-D-Ala termini (blue) of the lipid-PP-disaccharide-pentapeptide intermediate through a network of five hydrogen bonds (red lines). 
(c) The vancomycin-PG-D-Ala-o-Ala complex sterically occludes the transglycosylation/ transpeptidation steps of cell-wall assembly, 
which renders the cell susceptible to lysis through osmotic shock. 





Fig. 3. Comparison of Gram-positive and Gram-negative bacterial 
cell wall organization. In Gram-negative cells, the peptidoglycan 
(PG) layer (gold) and the inner membrane are enveloped by an 
outer membrane which prevents diffusion of glycopeptide anti- 
biotics to the PG layer. In contrast, the PG layer in Gram-positive 
bacteria is located on the outer surface of the cell membrane and 
is therefore susceptible to glycopeptide antibiotics. 
gene products,VanR,S,H and A. All five encoded proteins 
have since been overexpressed in E. coli, purified, and char- 
acterized by our group [7-141. Their functions, summa- 
rized in Table 1, reflect an elegant and ultimately a simple 
solution to engender resistance. As we shall note below, 
VanH,A and X are each enzymes that act in collaboration 
to produce an altered PG biosynthetic intermediate with 
reduced affinity for vancomycin.VanS is a sensor kinase 
andVanR is a response-regulator protein; these gene prod- 
ucts comprise a two-component transcriptional-activation 
system that can turn on transcription of vunH,A,X to 
induce the biosynthesis of the altered cell-wall intermediates. 
VanA: a D-Ala-D-Ala synthetase homolog that has acquired 
depsipeptide ligase activity 
VanA is a 39-kDa protein that was the first of the fiveVan 
proteins whose production was noted to be associated 
with phenotypically resistant enterococci. [15]. It has 28 % 
sequence identity to an E. coli enzyme, D-Ala-n-Ala ligase 
(Ddl), a catalyst in the PG biosynthetic pathway that is 
responsible for ATP-dependent ligation of two D-alanine 
molecules.The II-, D-dipeptide product of this reaction is 
subsequently added by the MurF enzyme to the tripeptide 
intermediate UDP-muramyl-L-Ala-D-y-Glu-m-DAP to 
yield the UDP-muramyl pentapeptide terminating in the 
N-acetylated D-Ala-D-Ala dipeptide unit. Once translo- 
cated from the cytoplasm to the periplasmic face of the 
cell membrane (as a C,, ip 1. id-PP-intermediate, see Fig. 
2b), this pentapeptide is the substrate for vancomycin 
binding. (Gram-positive bacteria can have lysine in place 
of the mere-diaminopimelate found in Gram-negative 
organisms.) Ddl homology was thus an intriguing property 
for the resistance proteinVanA, and, upon overproduction 
in and purification from E. co& the plasmid-encodedVan 
had not only a (unphysiologically) weak II-Ala-D-Ala 
dipeptide ligase activity, but also a new ability to activate 
the u-hydroxy acids u-lactate and D-hydroxybutyrate as 
nucleophilic cosubstrates to yield novel ester products 
(e.g., D-Ala-D-lactate; equation 1) [7]. No Ddl enzymes so 
far examined have this depsipeptide ligase activity exhib- 
ited byVanA, suggesting that this gain of catalytic function 
is intimately associated with resistance. A VanA homolog, 
Van& [6] from an enterococcal plasmid conferring low- 
level glycopeptide resistance also has depsipeptide ligase 
activity [ 161. 
D-Ala + D-lactate + ATP 
< 
D-Ala ,-D-Ala2 + ADP + 7 
D-Ala, -D-lactate + ADP + P 
(1) 
WhileVanA has yet to be crystallized, the X-ray structure 
of E. coli Ddl in complex with a phosphorylated transi- 
tion state analog and the product ADP has been solved 
1171, revealing the molecular architecture of this ligase 
family (Fig. 5a). As shown in Figure 5b, several protein 
side chains bind the dialkyl phosphinophosphate inhibitor 
and in particular, the side chain E-NH, of Lys215 coordi- 
nates both to ADP and to the P03*--group that has just 
undergone transfer as the Y-PO,~- ofATP to become the 
phosphate of the phosphinophosphate inhibitor. Lys215 is 
on a mobile o-loop (in yellow in Fig. 5) that has closed 
over the active site.Tyr216 is also on this loop and forms 
an H-bond triad with Serl50 and Glu15, which in turn 
coordinates the (-w-NH3 of the bound inhibitor. InVanA, 
several loop residues have changed including Tyr216, 
whereas Serl50 and Glu15 and several other active site 
residues are conserved. 
Mutagenesis studies indicated that Tyr216+Phe, 
Serl5O+Ala, and Glul5+Gln mutants of E. coli Ddl 
retain substantial dipeptide ligase activity [18]; close 
analysis of the Tyr216-+Phe and Serl50+Ala mutants, 
however, reveals that they have gained the depsipeptide 
ligase activity of VanA, catalyzing both amide (dipeptide) 
and ester (depsipeptide) synthesis (eq. 1) with acid and 
vans: Histidine kinase 
van,?: Response regulator 
vanH: o-Lactate dehydrogenase / ol-keto acid reductase 
vanA: D-Ala-D-Lactate figase 
vanX: D-Ala-D-Ala dipeptidase 
Fig. 4. Organization of the van gene cluster from the 
fnterococcus faecium BM4147 transposable element Tn 7545. 
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Table 1. Activities and functions of the products of the five van genes that are necessary and sufficient for vancomycin resistance. 
Protein Activity Function 
Vans Transmembrane histidine kinase Sensor protein that initiates signal transduction pathway 
VanR 
VanH 
Two-domain response regulator 
D-Specific a-keto acid reductase 
Accepts POs2- group from phospho-Vans, activates vanH,A,X transcription 
Generates D-lactate required for VanA action 
VanA Depsipeptide ligase for D-Ala-D-lactate Generates an ester D-Ala-D-lactate in competition with normal 
amide D-Ala-D-Ala 
VanX Zn2+-dependent D-Ala-D-Ala dipeptidase Selective removal of D-Ala-D-Ala allows accumulation of D-Ala-D- 
lactate for addition to growing UDP-muramyl-tripeptide 
alkaline pH optima, respectively (I.-S.P. & C.T.W., 
unpublished observations). These studies may reveal how 
an enzyme with depsipeptide ligase activity evolved from 
a dipeptide ligase. 
VanH is a D-hydroxy acid dehydrogenase 
The deduced amino-acid sequence of vanH has homol- 
ogy to a-keto acid reductases; it was thus possible that 
the reaction catalyzed by VanH produces substrates for 
the novel D-,D-depsipeptide ligase activity of VanA. To 
investigate the function of the vanH gene product, we 
expressed VanH in E. coli, purified it on a resin that is 
often used for NADPH binding proteins, and showed 
that the homogeneousVanH is an a-keto acid reductase, 
producing D-lactate or D-hydroxybutyrate from the 
readily available pyruvate or a-ketobutyrate substrates, 
respectively (Fig. 6a) [8]. In an enterococcal cell express- 
ing VanH and VanA (both necessary for resistance) the 
tandem action of the two enzymes would produce 
D-Ala-D-lactate from pyruvate and D-Ala in competition 
with D-Ala-D-Ala (see Fig. 6a). When UDP-muramyl 
peptide intermediates were examined in vancomycin- 
resistant enterococci, UDP-muramyl tetrapeptide ester 
species, terminating in D-Ala-D-lactate, were detected 
[19-221, proving that the D-, D-depsipeptide produced 
in the reaction catalyzed byVanH,A could be used as a 
substrate by MurF (Fig. 6b). 
VanX: A Zn2+-dependent D-, D-dipeptidase 
The vanX gene is co-transcribed with vanH,A, andVanX 
is also required to confer vancomycin resistance. The 
deduced amino-acid sequence of VanX gave no clue to its 
probable function, and its role remained obscure until 
Reynolds et al. [23] found evidence that it could 
hydrolyze D-aa-II-fia.We purifiedVanX from E. coli har- 
boring an overproduction vector, confirmed the dipepti- 
dase activity, showed a Zn-dependence and quantitated 
the selectivity for hydrolysis of u-&-D-Ala compared to 
Fig. 5. Structural studies on the VanA-related enzyme, D-Ala-D-Ala ligase (Ddl). (a) MOLSCRIPT [32] representation of the enzyme 
complexed with ADP and a phosphinophosphate transition state analog inhibitor (both are represented in ball-and-stick form). The 
o-loop (residues 205-2201, believed to be involved in substrate binding and catalysis, is shown in yellow. (b) Schematic representation 
of the active site residues with hydrogen bonds (dashed lines) to ADP (green) and a phosphinophosphate transition state inhibitor 
(blue). The w-loop is shown in yellow. Reprinted with permission from 1181. 
Vancomycin resistance Walsh et al. 25 
Fig. 6. Incorporation of D-Lactate pro- 
duced by VanH into cell wall precur- 
sors. (a) VanH functions as an 
a-ketoreductase to reduce pyruvate 
(R = Me) or a-ketobutyrate (R = Et), pro- 
ducing o-lactate or o-hydroxybutyrate, 
respectively. D-Lactate can serve as a 
substrate for VanA to produce D-Ala-D- 
lactate. (b) D-Ala-D-lactate can be used 
as a substrate by MurF to produce a 
UDP-muramyl tetrapeptide ester species 















(b) UDP-muramyl-L-Ala-D-y-Glu-L-Lys + D-Ala-D-Lactate 
ATP 
MurF 
ADP + Pi 
UDP-muramyl-L-Ala-D-y-Gtu-L-Lys-D-Ala-D-lactate 
D-da-D-lactate [ 111. Remarkably, the k&K, catalytic indicated that this pair of genes was clearly related to the 
efficiency ratio indicated a preference for D-Ala-D-Ala two-component regulatory systems that bacteria use to 
hydrolysis of >106-fold; k,,, for D-Ala-D-lactate was sense some environmental signal, transduce it across the 
clod, and this substrate has 250-fold lower binding a5n- membrane, and activate selective gene transcription to 
ity than D-Ala-D-Ala.This comparison explains the role of 
VanX in the antibiotic-resistant cell. A mix of D-Ala-D- 
Ala and D-Ala-D-lactate are produced by the enterococcal 0 
Ddl (dipeptide) and byVanA (dipeptide and depsipeptide) 
ligases, butVanX spares the depsipeptide while hydrolyzing 
A coo 
the dipeptide.Thus, in aVanH,A,X-producing bacterium, 
only D-Ala-D-lactate accumulates as a substrate for MurF, VanH 
and thus the PG advanced intermediates in these bacteria 
contain only D-Ala-D-lactate termini (Fig. 7). OH 
Vancomycin binds poorly to N-acyl-D-Ala-o-lactate L COON 
VanH,A,X-expressing enterococci are lOOO-fold more D-Ala, ATP 
resistant to vancomycin than sensitive enterococci [6]. To VanA 
evaluate the contribution of the N-acyl-D-Ala-D-lactate 
moiety in the PG termini to this decreased sensitivity, we 
assayed binding constants of vancomycin for NAc-D- 
Ala-D-Ala or for the corresponding NAc-D-Ala-D- 
lactate and measured a lOOO-fold reduction in K, for the 
depsipeptide [8]. Thus the loss of the hydrogen bond + 
tripeptide 
from the NH of the D-Ala-D-Ala dipeptide moiety to 
the vancomycin backbone carbonyl (Fig. 8) quantita- 
tively accounts for the resistance phenotype.The loss of 
one H-bond is the elegant and simple solution that can 
D-Ala-D-Ala - 2 D-Ala 
VanX 
spell life or death to the bacterium and, perhaps, to an Fig. 7. Alternative cell wall biosynthetic pathway of theVanH,A,X 
infected patient. proteins to produce peptidoglycan intermediates with D-Ah-D- 
lactate termini. Reduction of nvruvate bv bv the NADP-denendent 
Signal transduction by Van!3 and VanR 
In the absence of vancomycin, theVanH,A,X genes are 
transcriptionally inactive on a plasmid carrying the 
dehydrogenase VanH leads to the production of D-bate, which is 
an effective substrate for the ATP-dependent D-Ala-D-lactate depsi- 
peptide synthase VanA. The D-Ala-D-lactate depsipeptide formed 
by VanA is then taken forward by the adding enzyme MurF to 
uanRSEL4X operon (pIP816) [24].Vancomycin may be produce the muramyl-peptide-ester intermediate. VanX, a Zn*+- 
the direct inducing ligand or may act indirectly, for dependent dipeptidase that acts to specifically hydrolyze the 
example, by altering the synthesis/degradation balance of 
D-Ala-o-Ala dipeptide pool produced by the native, vancomycin- 
the cell wall. The DNA sequence of uunS and vu& 
sensitive biosynthetic pathway, effectively shunts the flux of the 
cell wall biosynthesis to theVanH,A pathway. 
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Fig. 8. Structures of the vancomycin complexes with N-Acyl-D-Ala-D-Ala (left) and N-Acyl-D-Ala-D-lactate (right). The hydrogen bond 
network responsible for the tight binding affinity to the drug is shown in red. The key hydrogen bond between the D-Ala amide NH and 
the vancomycin backbone, which is lost in the D-Ala-D-lactate complex, is highlighted in yellow. 
effect a desired response. Such systems, comprising a 
transmembrane sensor kinase (such as Vans) and cyto- 
plasmic response regulator (such as VanR), are found in 
bacterial responses to chemical gradients (chemotaxis), 
osmotic changes (EnvZ, OmpR in osmoregulation), 
nitrogen starvation, inorganic phosphate limitation, and 
dozens of other responses [25,26]. 
To test whetherVanS andVanR followed this precedent, 
we expressed the predicted cytoplasmic fragment of 
Vans [12] fused to maltose binding protein (MBP) in E. 
coli, purified it, and demonstrated autokinase activity, 
yielding a phospho-His164 form of the Vans protein. 
When homogeneousVanR was obtained [12] and incu- 
bated with phospho-His-MBP-Vans, the PO,*- group 
was transferred to a specific conserved aspartyl residue 
(Asp53) in the amino-terminal domain of VanR (Fig. 9). 
The carboxy-terminal half of the 27-kDaVanR protein 
was predicted to contain a DNA-binding domain. Using 
gel-shift assays and footprinting analysis, we demon- 
strated that the phospho-Asp form ofVanR bound more 
tightly than the dephospho form to symmetry elements 
in the promoter regions for the the vunH,A,X triad 
(PuQ,H) and for van&R [13]. Since Courvalin and co- 
wor k ers [24] have shown in vivo thatVanR acts as a tran- 
scriptional activator, it is highly likely that the 500-fold 
increase in K, for P 
7 
binding by phospho-VanR 
compared to VanR co% ates with increased transcrip- 
tion of vanH,A,X (Fig. 10). The signal-transduction 
pathway leading to vancomycin resistance clearly pro- 
ceeds via the receptor histidine kinase/phosphoaspartyl 
transcriptional activator molecular logic in which exter- 
nal ligand binding is translated into interprotein phos- 
phoryl group movement as the cytoplasmic information 
transfer currency. Selective transcription of vanH,A,X 
yields the three catalysts that remodel the biosynthetic 
termini of PG intermediates. The ester linkage in the 
PG-I>-Ala-II-lactate strands is an effective substrate for 
crosslinking by the penicillin-sensitive transpeptidase, so 
there is no osmotic liability to the Enferococcus in this 




activation of vanH,A,X 
Fig. 9. Phosphotransfer relay in the VanS-VanR two-component signal-transduction system. Vans undergoes autophosphorylation with 
ATP on a histidine residue (His1 64) to yield the acid-labile, phosphorylated kinase. The phosphate group is then transferred to an 
aspartate residue on VanR (Asp53) through an Mg2+-activated intermediate. 
Vancomycin resistance Walsh et al. 27 
Fig. 10. Activation of transcription of the 
vanH,A,X multicistronic RNA by the 
Vans-VanR two-component system. 
Upon activation of VanS by a sensory 
ligand (magenta), VanS undergoes 
autophosphorylation at a histidine 
residue (His1 64). Subsequent transfer of 
the phosphate group to an aspartate 
group on VanR (Asp53) results in a con- 
formational change on VanR to promote 
dimerization and DNA binding. Binding 
of phospho-VanR to the vanH,A,X pro- 
moter (P& results in transcriptional 
activation, while phospho-VanR binding 
to the vanR,S (P,,&promoter results in 
repression of transcription. 
Cell membrane 
Vans ATP ADP 
VanR P-VanR 
Repressor Activator 
Opportunities for intervention to reverse 
vancomycin resistance 
With the molecular logic of each of the five necessary 
and sufficient vancomycin-resistance proteins revealed, 
the opportunities increase to intervene and convert van- 
comycin resistance back to sensitivity. On the one hand, 
rational approaches may be used for inhibition of the 
novel VanA depsipeptide ligase and for the unique 
Zn*+-dependent VanX D-, D-dipeptidase, and slow- 
binding inhibitors have been described for each of these 
proteins [7-l 11. On the other hand, one can establish 
screens against any of the five Van proteins. Intev alia, a 
screen that blocks phosphoryl transfer from sensor histi- 
dine autokinases to their cognate response regulators 
should be of general antibacterial utility [27]. Recent 
screening efforts against enterococci have yielded effec- 
tive glycopeptide-antibiotic variants with increased 
hydrophobicity 1281, supporting the hypothesis that the 
equilibria of glycopeptide dimerization 1291 (which 
results in bidentate ligation to peptidoglycan termini) 
and the membrane avidity of the glycopeptide are 
important factors in the antibacterial potency of this 
class of antibiotics. 
Finally a note on lessons from the past that may be rele- 
vant to future study of vancomycin/antibacterial resis- 
tance. In speculating on the molecular origin of the five 
van genes collected for high level resistance, we note that 
certain Gram-positive bacteria such as Leuconostoc, lacto- 
bacilli, and pediococci are intrinsically resistant to the 
vancomycin class of glycopeptides. These bacteria have 
now been examined and found to contain PG-D- 
Ala-II-lactate termini in their cell wall intermediates 
[30,31]. It is likely that this will also be the molecular 
mechanism for immunity by the vancomycin-producing 
Amycolatopsis ovient&.The ability to collect five genes to 
fashion the elegant, but simple, amide to ester switch in 
the vancomycin-resistance strategy, reinforces the con- 
centrated ability of large microbial populations to go to 
great Iengths to combat antibiotic action. 
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